CompanyGraph
Shanxi Zhendong Pharmaceutical Co., Ltd.
300158 · SZSE · China
zdjt.comFinancials as of FY2024 · latest on file
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
5.39BCNY800.26M · vs all stocks (USD)
Revenue (TTM)
2.68BCNY397.69M · vs all stocks (USD)
Profit Margin
-11.33%Beta
0.1790xvs all stocks
52-Week Change
-34.34%vs all stocks
Market Capitalization
5.39BCNY800.26M · vs all stocks (USD)
Enterprise Value
4.96BCNY737.30M · vs all stocks (USD)
Forward P/E
13.22xPrice to Sales (TTM)
2.01xPrice to Book (MRQ)
1.61xEnterprise to Revenue
1.85xEnterprise to EBITDA
-25.51xGross Margin
53.36%Profit Margin
-11.33%Operating Margin
-0.64%Return on Assets (TTM)
-4.24%Return on Equity (TTM)
-8.81%Revenue (TTM)
2.68BCNY397.69M · vs all stocks (USD)
Revenue per Share (TTM)
2.67CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-14.00%Gross Profit (TTM)
1.37BCNY203.79M · vs all stocks (USD)
EBITDA (TTM)
-194.60MCNY-28.90M · vs all stocks (USD)
Net Income (TTM)
-303.26MCNY-45.04M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-3.05%Operating Cash Flow (TTM)
-434.53MCNY-64.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-319.53MCNY-47.46M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
-37.37MCNYFY2024 · Dec 31, 2024Revenue
2.97BCNYFY2024 · Dec 31, 2024Cost of Goods Sold
1.56BCNYFY2024 · Dec 31, 2024Gross Profit
1.41BCNYFY2024 · Dec 31, 2024Operating Income
-338.83MCNY-50.32M · vs all stocks (USD)
Pre-tax Income
-1.32BCNYFY2024 · Dec 31, 2024Income Tax Expense
17.92MCNYFY2024 · Dec 31, 2024Net Income
-1.33BCNYFY2024 · Dec 31, 2024EBIT
-1.31BCNYFY2024 · Dec 31, 2024EBITDA (Income Statement)
-777.77MCNYFY2024 · Dec 31, 2024Research & Development
351.48MCNYFY2024 · Dec 31, 2024Selling, General & Administrative
1.01BCNYFY2024 · Dec 31, 2024Other Operating Expenses
30.85MCNYFY2024 · Dec 31, 2024Non-operating Interest Income
5.67MCNYFY2024 · Dec 31, 2024Non-operating Interest Expense
3.61MCNYFY2024 · Dec 31, 2024EPS (Basic)
-1.30CNYFY2024 · Dec 31, 2024EPS (Diluted)
-1.30CNYFY2024 · Dec 31, 2024Basic Shares Outstanding
1.02BSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
1.02BSharesFY2024 · Dec 31, 2024Net Income from Continuing Operations
-1.33BCNYFY2024 · Dec 31, 2024Minority Interests (P&L)
4.38MCNYFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00CNYFY2024 · Dec 31, 2024Operating Cash Flow
-1.04BCNYFY2024 · Dec 31, 2024Free Cash Flow
-1.33BCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
558.02MCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-1.33BCNYFY2024 · Dec 31, 2024Other Non-cash Items
9.38MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
115.00MCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
173.23MCNYFY2024 · Dec 31, 2024Capital Expenditures
-290.71MCNYFY2024 · Dec 31, 2024Net Acquisitions
988.38KCNYFY2024 · Dec 31, 2024Purchase of Investments
-6.06BCNYFY2024 · Dec 31, 2024Sale of Investments
6.39BCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
39.51MCNYFY2024 · Dec 31, 2024Long-term Debt Issuance
38.11MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-53.35MCNYFY2024 · Dec 31, 2024Common Dividends Paid
-584.65KCNYFY2024 · Dec 31, 2024Other Financing Charges
-78.67MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
-94.49MCNYFY2024 · Dec 31, 2024Shares Outstanding
1.01BSharesUpdated Aug 19, 2026Float Shares
687.76MSharesUpdated Aug 19, 2026% Held by Insiders
40.42%vs all stocks
% Held by Institutions
0.34%vs all stocks
Total Cash (MRQ)
782.89MCNY116.28M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.7890CNYUpdated Aug 19, 2026Total Debt (MRQ)
249.72MCNY37.09M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0755xCurrent Ratio (MRQ)
2.32xBook Value per Share (MRQ)
3.37CNYUpdated Aug 19, 2026Total Assets
4.98BCNY740.03M · vs all stocks (USD)
Total Current Assets
3.22BCNYFY2024 · Dec 31, 2024Total Liabilities
1.32BCNYFY2024 · Dec 31, 2024Total Non-current Assets
1.77BCNYFY2024 · Dec 31, 2024Total Non-current Liabilities
67.43MCNYFY2024 · Dec 31, 2024Total Current Liabilities
1.26BCNYFY2024 · Dec 31, 2024Cash
540.73MCNYFY2024 · Dec 31, 2024Cash Equivalents
43.86MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents
584.59MCNYFY2024 · Dec 31, 2024Other Short-term Investments
989.62MCNYFY2024 · Dec 31, 2024Accounts Receivable
519.55MCNYFY2024 · Dec 31, 2024Inventory
775.98MCNYFY2024 · Dec 31, 2024Accounts Payable
328.01MCNYFY2024 · Dec 31, 2024Short-term Debt
40.12MCNYFY2024 · Dec 31, 2024Other Current Liabilities
11.36MCNYFY2024 · Dec 31, 2024Long-term Debt
1.09MCNYFY2024 · Dec 31, 2024Common Stock (Book)
1.01BCNYFY2024 · Dec 31, 2024Retained Earnings
-1.39BCNYFY2024 · Dec 31, 2024Total Shareholders' Equity
3.66BCNY543.62M · vs all stocks (USD)
Treasury Stock
2.84MCNYFY2024 · Dec 31, 202452-Week Low
4.47CNYUpdated Aug 19, 202652-Week High
10.27CNYUpdated Aug 19, 202652-Week Change
-34.34%vs all stocks
Beta
0.1790xvs all stocks
50-Day MA
5.02CNYUpdated Aug 19, 2026200-Day MA
5.79CNYUpdated Aug 19, 2026Avg 10-Day Volume
48.77MSharesUpdated Aug 19, 2026Avg 30-Day Volume
28.58MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-0.3000CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Center Laboratories, Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Anglikang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Konruns Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengda Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule